|Mr. Amit D. Munshi||Pres, CEO & Director||644.43k||N/A||49|
|Mr. Kevin R. Lind||Chief Financial Officer and Exec. VP||342.33k||N/A||41|
|Mr. Steven W. Spector J.D.||Exec. VP, Gen. Counsel and Sec.||638.3k||N/A||52|
|Mr. Vincent E. Aurentz||Chief Bus. Officer and Exec. VP||274.24k||N/A||49|
|Ms. Cate Scanlon||VP of Global HR||N/A||N/A||N/A|
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The companys proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 4.